Related Experiment Video

Updated: Aug 14, 2026

Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis
06:56

Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis

Published on: September 26, 2012

The effect of anti-thymocyte antiserum in progressive myasthenia gravis

B Pirofsky

    Annals of the New York Academy of Sciences
    |January 1, 1981
    PubMed

    The therapeutic effect of goat anti-human thymocyte antiserum globulin (ATG) was assessed in ten patients with myasthenia gravis. Five patients had undergone prior thymectomy. All subjects had far-advanced, debilitating and progressing disease poorly responsive to classic anticholinesterase therapy. Prolonged, low dose ATG therapy was used with 1.0-2.6 grams/protein administered intramuscularly over a 28-73 period. Depression of cellular immunity was observed with anti-thymocyte antiserum was more profound in patients with a prior thymectomy. Therapeutic responses of varying degrees were noted in 8 out of 10 patients. Completion of a course of ATG and discontinuation of the drug did not lead to acute relapse states. Follow-up examinations for over five years have been maintained. A mean remission period of approximately two years was observed. It is suggested that this therapy deserves further evaluation. Subjects with prior thymectomy and progressive disease may represent the most ideal candidates.

    More Related Videos

    Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells10:32

    Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

    Published on: June 5, 2015

    Antigenic Liposomes for Generation of Disease-specific Antibodies10:31

    Antigenic Liposomes for Generation of Disease-specific Antibodies

    Published on: October 25, 2018

    Related Concept Videos

    Chemical Synapses01:26

    Chemical Synapses

    Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
    Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
    Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

    Indirect-Acting Cholinergic Agonists: Pharmacological Actions

    Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
    At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
    Myasthenia Gravis: Overview and Treatment01:20

    Myasthenia Gravis: Overview and Treatment

    Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
    These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
    Myasthenia Gravis: Diagnostic Tests01:15

    Myasthenia Gravis: Diagnostic Tests

    Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
    The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
    Chemical Synapses01:26

    Chemical Synapses

    Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
    Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
    Myasthenia Gravis ll: Pathophysiology01:22

    Myasthenia Gravis ll: Pathophysiology

    The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...